Hepatic Staging & CLD Complications Pathway

MELD-Na, Child-Pugh & CLD Complications (HRS, HPS, mDF) · v1.2

How to use this tool: Enter the standard liver biochemistry and clinical findings. The tool returns the Child-Pugh class, for operative risk and drug dosing, alongside the MELD-Na score for 90-day mortality and transplant priority.

If the liver disease is alcohol-related, two other tools apply during this admission. Quantify the intake and screen for a use disorder with the Alcohol Unit Calculator and AUD Assessment. More urgently, a patient admitted with alcoholic hepatitis or decompensated cirrhosis who has stopped drinking will withdraw, usually on day 2 or 3: the Alcohol Withdrawal: CIWA-Ar and Thiamine Protocol covers that, and it selects lorazepam rather than chlordiazepoxide once cirrhosis is decompensated. Note that confusion in this patient is hepatic encephalopathy until proved otherwise, and the benzodiazepines that treat withdrawal will worsen it.

1. Laboratory Biomarkers

Total Bilirubin (mg/dL)

Albumin (g/dL)

INR

Serum Sodium (Na⁺) (mEq/L)

Serum Creatinine (mg/dL)

Dialysis ≥ 2 times in past week?

2. Clinical Parameters

Ascites

Hepatic Encephalopathy

Complications Engine: Evaluates criteria for specific decompensating events (Alcoholic Hepatitis severity, Hepatorenal Syndrome, Hepatopulmonary Syndrome). Only fill out the section relevant to your patient's presentation.

A. Maddrey's Discriminant Function (Alcoholic Hepatitis)

Patient PT (seconds)

Control PT (seconds)

Total Bilirubin (mg/dL)

B. Hepatorenal Syndrome (HRS-AKI) Criteria

Confirmed Cirrhosis with Ascites Acute Kidney Injury (sCr rise ≥ 0.3 mg/dL within 48h OR ≥ 50% from baseline) No improvement in sCr after ≥ 2 days of diuretic withdrawal AND volume expansion with Albumin (1g/kg/day) Absence of shock, nephrotoxins (NSAIDs/Aminoglycosides), or macroscopic parenchymal kidney disease

C. Hepatopulmonary Syndrome (HPS) Criteria

PaO₂ on Room Air (mmHg)

Widened A-a Gradient (≥ 15 mmHg, or ≥ 20 mmHg if age > 64) Evidence of Intrapulmonary Shunting (Positive agitated saline contrast echocardiogram)

Academic Pearls & Pathophysiology

2. Pathophysiology: Why Sodium in MELD-Na?

The original MELD score relied only on Bilirubin, INR, and Creatinine. However, in advanced cirrhosis, severe portal hypertension triggers massive release of systemic vasodilators (like nitric oxide). This splanchnic vasodilation causes a drop in effective arterial blood volume, which triggers the baroreceptors to release massive amounts of non-osmotic Anti-Diuretic Hormone (ADH). This ADH causes profound free-water retention, resulting in dilutional hyponatraemia. Therefore, a low serum sodium (< 135 mEq/L) is an independent surrogate marker for extreme portal hypertension and poor survival, which is why it was added to the transplant allocation formula.

3. Practice Advisory: Blind Steroids in Alcoholic Hepatitis

The Sepsis Caution in India: A Maddrey's Discriminant Function (mDF) ≥ 32 mathematically indicates severe alcoholic hepatitis with a high 1-month mortality, classically warranting corticosteroids (Prednisolone 40mg/day). HOWEVER, in the Indian clinical context, you MUST aggressively rule out occult infections (UTI, SBP, pneumonia) and latent Tuberculosis before initiating high-dose steroids. Steroids in a cirrhotic patient with untreated sepsis will cause rapid, fatal septic shock.

4. Illness Scripts: AKI in Cirrhosis

Condition	Pathophysiology	Volume Challenge Response
Pre-Renal Azotaemia	True volume depletion (over-diuresis, GI bleed, severe vomiting/diarrhoea).	Rapidly improves with IV Albumin/Fluids.
Hepatorenal Syndrome (HRS-AKI)	Extreme splanchnic vasodilation leading to compensatory, intense renal vasoconstriction. The kidneys are histologically normal but functionally starved of blood.	Refractory to volume expansion. Requires vasoconstrictors (Terlipressin) + Albumin to reverse splanchnic pooling.
Acute Tubular Necrosis (ATN)	Direct structural damage to renal tubules (ischaemic shock, nephrotoxic drugs, contrast).	Refractory to volume expansion. Urine will show muddy brown casts.

5. Strict Contraindications in Cirrhosis

Avoid NSAIDs & ACE-Inhibitors: Cirrhotic patients rely heavily on renal prostaglandins to keep their afferent renal arterioles dilated and maintain GFR. Administering an NSAID (which blocks prostaglandins) or an ACE-Inhibitor will instantly precipitate acute renal failure.

Abbreviations: A-a (Alveolar-Arterial) · ACE (Angiotensin-Converting Enzyme) · ADH (Antidiuretic Hormone) · AKI (Acute Kidney Injury) · ATN (Acute Tubular Necrosis) · AUD (Alcohol Use Disorder) · CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) · CLD (Chronic Liver Disease) · GFR (Glomerular Filtration Rate) · GI (Gastrointestinal) · HPS (Hepatopulmonary Syndrome) · HRS (Hepatorenal Syndrome) · HRS-AKI (Hepatorenal Syndrome - Acute Kidney Injury) · INR (International Normalised Ratio) · mDF (Maddrey's Discriminant Function) · MELD (Model for End-Stage Liver Disease) · MELD-Na (Model for End-Stage Liver Disease - Sodium) · Na⁺ (Sodium) · NSAID (Non-Steroidal Anti-Inflammatory Drug) · PaO₂ (Partial Pressure of Arterial Oxygen) · PT (Prothrombin Time) · SBP (Spontaneous Bacterial Peritonitis) · sCr (Serum Creatinine) · TB (Tuberculosis) · UTI (Urinary Tract Infection)

Algorithm References & Evidence Base

Pugh RN, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.
Organ Procurement and Transplantation Network (OPTN). Policies: MELD Score. US Department of Health and Human Services.
Maddrey WC, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199.
Angeli P, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974.

How to Cite This Tool

AMA Style:
Umakanth S. Hepatic Staging & CLD Complications Pathway. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Hepatic Staging & CLD Complications Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Category Risk Scores & Diagnostic PathwaysPathway

Specialties Gastroenterology & Hepatology

Written and maintained by Dr Shashikiran Umakanth.
Last revised: 29 July 2026

Back to All Medical Calculators & Pathways